Anaptys Biosciences Inc.
This article was originally published in Start Up
According to the CEO of Anaptys Biosciences, therapeutic antibodies will continue to be the single largest growing segment in pharmaceuticals, but the number of companies providing solutions in this area is decreasing following a number of acquisitions. Anaptys will fill the gap with its somatic hypermutation technology platform for therapeutic antibody discovery and optimization. The platform replicates the natural process of mutagenesis occurring in B cells as part of the immune response, involving steps of immunoglobulin recombination, mutation, affinity maturation and selection.
You may also be interested in...
AnaptysBio has gained another big partner in Celgene for its antibody discovery platform; bringing Celgene further into biologics.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibody Start-Ups," features profiles of 4-Antibody, Anaptys Biosciences and f-star. Plus these Start-Ups Across Health Care: Actuality Medical, INBONE Technologies, Interrad Medical and Tethys BioScience.
It's a good time to be an antibody company. As almost all the Big Pharma fall over each other to grab whatever antibody assets they can, investors backing still-independent firms are rubbing their hands in glee. One of the companies we profile this month claims it has found a novel route around the one major drawback to antibody development--the dreaded IP blackout. But whatever their trump card-whether they're improving existing antibodies, like Anaptys and 4-antibody, or, like f-star, creating antibody fragments, interest from strategic partners is guaranteed.